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Abstract
Background: We investigated whether information in ClinicalTrials.gov would impact the conclusions of five
ongoing systematic reviews.
Method: We considered five reviews that included 495 studies total. Each review team conducted a search of
ClinicalTrials.gov up to the date of the review’s last literature search, screened the records using the review’s
eligibility criteria, extracted information, and assessed risk of bias and applicability. Each team then evaluated the
impact of the evidence found in ClinicalTrials.gov on the conclusions in the review.
Results: Across the five reviews, the number of studies that had both a registry record and a publication varied
widely, from none in one review to 43% of all studies identified in another. Among the studies with both a record
and publication, there was also wide variability in the match between published outcomes and those listed in
ClinicalTrials.gov. Of the 173 total ClinicalTrials.gov records identified across the five projects, between 11 and 43%
did not have an associated publication. In the 14% of records that contained results, the new data provided in the
ClinicalTrials.gov records did not change the results or conclusions of the reviews. Finally, a large number of
published studies were not registered in ClinicalTrials.gov, but many of these were published before ClinicalTrials.
gov’s inception date of 2000.
Conclusion: Improved prospective registration of trials and consistent reporting of results in ClinicalTrials.gov would
help make ClinicalTrials.gov records more useful in finding unpublished information and identifying potential biases.
In addition, consistent indexing in databases, such as MEDLINE, would allow for better matching of records and
publications, leading to increased utility of these searches for systematic review projects.
Background
Information biases, including publication bias, time-lag
bias, selective outcome reporting bias, and selective ana-
lysis bias, are major threats to the validity and usability of
systematic reviews. Systematic reviewers have pursued
two method approaches for dealing with information bias.
One is to detect (and possibly correct results for) informa-
tion bias based only on the identified studies (e.g., using
funnel-plot-based methods [1–4] or sensitivity analyses to
account for possible missing data [5–7] or comparing
outcomes listed under Methods versus those reported
under Results in published manuscripts [8]). A second is
to examine trial registries, survey researchers, and peruse
the gray literature to identify unpublished study results or
ongoing studies.
Clinical trial registries that include prospective regis-
tration of study protocols, as well as in some cases sum-
marized results (e.g., the National Library of Medicine
ClinicalTrials.gov registry and registry networks, such as
International Clinical Trials Registry Platform [ICTRP]),
are a good source of this information. Regulations estab-
lished in 1997 and expanded under the Food and Drug
Administration Amendments Act of 2007 [9, 10],
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National Institutes of Health policy, and International
Committee of Medical Journal Editors (ICMJE) guidance
[11] have motivated industry sponsors and academic
researchers to prospectively register their studies. This
collection of policies includes requirements for register-
ing studies including documenting type of study, inter-
vention, trial phase, funding source, and outcomes, and
types of data to be included within a study record. En-
forcement of these policies has evolved since the launch
of ClinicalTrials.gov in 2000. Clarifications on what in-
formation should be included in ClinicalTrials.gov have
been issued to the research community to ensure com-
pliance and timely submission of appropriate data to the
registry [12]. Advocates of clinical trial registration
emphasize the role of registry platforms to disseminate
aggregated results to researchers, clinicians, and study
participants. Registries enhance transparency by provid-
ing an inventory of studies that are in progress or have
been completed [13, 14].
Empirical analyses of prospective registration of stud-
ies (defined here as registration of investigational studies
prior to enrollment of the first patient or, for observa-
tional studies, prior to initial analyses) can inform on the
time between study completion and publication, the
number of unpublished studies, the fidelity of studies to
registered protocols, and the congruence of study results
between registry records and publications [15–18]. The
current Agency for Healthcare Research and Quality
Evidence-based Practice Center (EPC) Program guidance
recommends searching trial registries [19], but it is
labor-intensive and the utility of the additional effort
required is uncertain.
The objective of this project was to assess whether
information from ClinicalTrials.gov would affect the
conclusions of five ongoing systematic reviews.
Methods
To assess the impact of information derived from Clin-
cialTrials.gov on systematic reviews, five ongoing sys-
tematic reviews were selected. Our goal was to measure
prospectively the resource use and payoff of Clinical-
Trials.gov searches in real-time across a variety of topics.
The full method sections for each project are repro-
duced in Additional file 1.
Selection of reviews
The Agency for Healthcare Research and Quality sent a
request for proposals to members of their network of
evidence-based practice centers for analysis of the evalu-
ation of ClinicalTrials.gov data in ongoing reports. From
the submitted proposals, they chose to fund five projects
that were based in different clinical areas and popula-
tions and spanned different types of interventions, in
order to evaluate the impact across as broad a range as
possible. The selected reviews include as follows:
Prevention and treatment of diabetic peripheral
neuropathy [20], Evaluating treatment for infertility [21],
Omega-3 fatty acids and cardiovascular disease [22],
tympanostomy tubes in children with otitis media [23],
Strategies to improve mental health care for children
and adolescents [24].
Definition of terms
For the purposes of this project, a study is the actual
research conducted, a record is the ClinicalTrials.gov
report of the study, and a publication is a journal article
report of the study. Each of the five case studies is
referred to as a project. The original systematic review
on which each project is based is the report.
General methods followed by all teams
These five projects were conducted by four separate
EPCs to ensure consistency in searching and screening
between the systematic reviews and the report [25–29].
Details are given in Table 1. In general, they included
the following: A search of ClinicalTrials.gov at the date
of the original review’s update search, screening the
records using the original review’s eligibility criteria,
extracting information from the records, and assessing
risk of bias and applicability. Relevant studies identified
in registry records were compared to those included in
the review.
Studies were matched to publications using the cita-
tions listed in the “More Information” section of the
Study Details tab of the ClinicalTrials.gov record or the
National Clinical Trial (NCT) number given in the
MEDLINE® record. Where no match could be identified
using the NCT identifier, the teams manually searched
MEDLINE using terms for the interventions and princi-
pal investigator as search criteria.
Each team abstracted selected variables from the
ClincalTrials.gov records to determine whether key
study design variables and reported outcomes
matched information in the published manuscript.
Variables abstracted matched those extracted from re-
ports for the systematic reviews and included date of
completion, number of study arms and N of the
study, intervention description, study design, out-
comes measures, analysis approach and subgroup ana-
lyses, numerical results, and risk of bias. Each team
then evaluated the impact of the evidence found in
the registries on the conclusions and strength of evi-
dence in the report in different ways. The project
protocols were prospectively published on the AHRQ
Web site (https://effectivehealthcare.ahrq.gov/topics/trans-
parency-reporting/overview/).
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Important method variations between projects
Variations between projects include the following: Two
projects also searched the World Health Organization’s
(WHO) International Clinical Trials Registry Platform
(ICTRP) [25, 26]. This registry does not include results,
but the team was able to compare other study details for
these records. These results are included in the reported
results for these two projects. A second team contacted
the authors of included studies (via phone and email) to
collect information about rationale for use or non-use of
ClinicalTrials.gov or other archive sites for information
on study conduct and processes [27]. In addition, four of
the five projects included a plan to incorporate new
results in meta-analyses where feasible [25, 26, 28, 29].
Assessing the impact of records on the review
In assessing the impact on the systematic review of the
records found, the teams looked at three categories of
studies. The first category included studies that had both
a ClinicalTrials.gov record and a publication. For these
studies, each team compared the record to the publica-
tion, in terms of design details, population description,
sample size, details about the interventions, outcomes,
and results if they were given. If results were identified
in the record that were not found in the publication,
these were incorporated into the review as applicable.
The second category included studies that had a record
in ClinicalTrials.gov but no publication. For these stud-
ies, the team documented the study status (whether it
was completed, discontinued, or ongoing) and relevant
dates. If the record reported results, these were extracted
using the forms used for the original review and incor-
porated into the systematic review if they were applic-
able and usable. The final category included studies with
a publication but no record. These studies were evalu-
ated for potential reasons why they were not included in
the registry.
Results
As Table 2 shows, the proportion of ClinicalTrials.gov
(and ICTRP) records that could be matched to publica-
tions ranged from a low of 3% of all studies identified in
either the literature or ClicinalTrials.gov search for the
tympanostomy tubes review to 43% in the infertility
review. Between 11 and 30% of records did not have an
associated publication. Of the records without associated
publications, the number of records that were more than
3 years old varied widely. The cutoff of 3 years was
Table 1 Methods employed across projects assessing utility of ClinicalTrials.gov searches in ongoing systematic reviews
Protocol element Diabetic peripheral
neuropathy
Infertility Omega-3 and CVD Mental health Tympanostomy
tubes
Search ClinicalTrials.gov using terms
adapted from the systematic review
x x x Also searched
ICTRP
x x Also searched
ICTRP
Screened records using same criteria
as systematic review
x x x x x
Data Extraction from
ClinicalTrials.gov
x x x x x
Compared records to publications x x x x Also emailed authors x
Population x x x x x
Intervention x x x x x
Outcome definition x x x x x
Population baselines x x x x x
Results x x x x x
Risk of bias x x
When there was only a
ClinicalTrials.gov record
Recruitment status (as listed in
ClinicalTrials.gov)
x x x x x
Dates* (study start and
completion dates)
x x x x x
Results reported in
ClinicalTrials.gov
x x x No studies with results reported
only in records
x
Re-analyzed ongoing review
with new results
x No records had
usable results
No records had
usable results
The systematic review did not
have quantitative analyses
No records had
usable results
Country (site information in
ClinicalTrials.gov)
x x
*Extracted dates from ClincialTrials.gov records to establish how many are more than 3 years old
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chosen because it indicated that there had been sufficient
time for them to go through the publication process. Fi-
nally, in most cases, most of the publications in the sys-
tematic reviews were not registered in ClinicalTrials.gov.
Of these, most were conducted and completed prior to
ClinicalTrials.gov’s inception date or were not conducted
in the USA. Despite the fact that four of the five projects
intended to rerun meta-analyses with new results to meas-
ure changes in magnitude and direction of effect, only one
project was able to find new study-level results that would
allow them to do so. These results are presented in the
section “Studies that had a ClinicalTrials.gov record but
no publication” below.
Studies that had both a record and publication
We found relatively good agreement between the regis-
tration records and publications, where we found both,
especially when it came to the design elements and
intervention descriptions, as well as in specific results
where they were included in the record. We did find
some discrepancies in lists of outcomes between how
the outcomes were pre-specified in the record and
reported in the publication (shown in Table 3). For
example, in the omega-3 project, the team found that of
all the outcomes, 71 (a majority) were recorded in both
ClinicalTrials.gov and the publications; 2 (both clinical
outcomes) were reported in only ClinicalTrials.gov
records and not included in the publications; and 25
appeared for the first time in the publications. In this
report, these were primarily intermediate outcomes (e.g.,
lipids and blood pressure), though in three papers they
were clinical outcomes, including nonfatal stroke, myo-
cardial infarction, and revascularization. The direction,
magnitude, and statistical significance of study results
for specific outcomes were similar whether they were
pre-specified in ClinicalTrials.gov or not (e.g., omega 3
groups had significantly lower triglycerides in all papers,
regardless of whether triglycerides were a pre-specified
outcome in the record or not). In terms of primary and
secondary outcomes, we found that, while it is easy to
identify the primary outcome in the record, it is more
challenging in the papers, because it is seldom specified
and different papers from the same study may report
different outcomes as though they were primary. Thus,
we were not able to draw any conclusions about type of
outcome.
It is possible that this table is an underestimation of
the actual discrepancies between prespecified and
reported outcomes, because many of the records were
not prospectively registered (defined as registration prior
to enrollment of the first patient for RCTs or prior to
initial analyses for observational studies). For example,
Table 2 Numbers of ClinicalTrials.gov records and publications found
Diabetic peripheral neuropathy Infertility Omega-3 and CVD Mental health Tympanostomy
tubes
Total studies with ClinicalTrials.gov
record or publication
106 28 141 20 200
Studies with both ClinicalTrials.gov
record and publication
All (%)
30 (28) 12 (43) 26 (18) 4 (20) 6 (3)
ClinicalTrials.gov record only
All (%) 23 (22) 4 (14) 43 (30) 3 (15) 22 (11)
With results/all • 7/23 • 4/4 • 0/43 • 0/3 • 2/22
> 3 years old/all • 13/23 • 2/4 • 9/43 • 0/3 • 5/22
Total studies with ClinicalTrials.gov record or publication
All (%) 53(50) 12 (43) 72 (52) 13 (65) 172 (86)
Since 2000/all • 30/53 • 0/12 • 58/72 • 13/13 • 97/172
Table 3 Outcomes reported in records versus publications
Diabetic peripheral neuropathy Infertility Omega-3 and CVD Mental health Tympanostomy
tubes
Outcomes reported in both ClincalTrials.gov
record and Publication n/N (percent)
18/45 (40) 11/20 (55) 71/98 (72) 0/7 (0) 24/35 (69)
Outcomes reported in ClinicalTrials.gov record
only (percent)
5/45 (11)* 3/20 (15) 2/98 (2) 2/7 (29) 8/35 (23)
Outcomes reported in Publication only
(percent)
22/45 (49) 6/20 (30) 25/98 (26) 5/7 (71) 3/35 (8)
*One record had results
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in the tympanostomy tubes project, of the 28 total rele-
vant records, only 15 were prospectively registered, and
none of the six records with matching publications was
prospectively registered [25].
Studies that had a ClinicalTrials.gov record but no
publication
Between 11 and 30% of all studies had a record but no
associated publication (Table 1). However, these numbers
may not be totally accurate, because we found it difficult
to match records to publications, especially where trials
were not indexed to crosswalks between PubMed and
ClinicalTrials.gov. The authors of the treatment for infer-
tility project attempted to automate the matching process
to streamline finding relevant records but were unable to
do so. They planned to use a semi-automated process
within the bibliographical database (EndNote® Version X7;
Thomson Reuters, Philadelphia, PA), but this approach
proved infeasible due to inconsistent assignment of NCT
identifiers to EndNote fields [28]. Thus, all matching in all
projects was accomplished by manual review, using NCT
identifiers in PubMed records, abstracts, or full-text arti-
cles or using the “related citations” sections of Clinical-
Trials.gov records.
In general, teams found that the records without match-
ing publications were more recent: between 43.5 and
100% were ongoing or had completion dates within the
previous 3 years. Figure 1 is from the Omega-3 Fatty
Acids and Cardiovascular Disease project. In Fig. 1, each
line represents a record, with the dots representing the
start and end dates as reported in the registry. Red lines
represent studies that were in both the review and the
registry; studies represented by black lines did not have a
corresponding publication. The mean start date of the
studies included in the review (indicated by the red dashed
line) was about 5 years earlier than the mean start date of
the studies not in the review (indicated by the black
dashed line). In addition, many of the studies not in the
review were not completed at the time of the search (blue
line), which explains why they did not have publications
or results [26].
In the review on diabetic peripheral neuropathy, the
team found that more than half of the unpublished stud-
ies (i.e., with ClinicalTrials.gov records only) were com-
pleted more than 3 years earlier (13 of 23, 56.5%),
enough time that the results should be published. Seven
of these 13 studies reported results in ClinicalTrials.gov
(Table 1), suggesting either completion of the study or
reporting of interim results. The team also found that,
for almost all interventions, the new results had no or
minimal effect on the findings of the review. Updated
meta-analyses illustrated a pattern of ClinicalTrials.gov
records reporting a less-dramatic effect of treatments on
pain compared with placebo than the effects reported in
the published studies. For both treatments (pregabalin
and oxycodone), the overall pattern appeared to be tem-
poral rather than suggestive of publication bias [29]. These
results could be a result of time-lag bias or a reflection of
the fact that early studies are usually done in the popula-
tions most likely to benefit from the intervention.
Interestingly, only one new article was identified
through this process. One team found a new publication
from a study included in the original review, which had
been published since the last update of the review
search. The results in this newly identified manuscript
were added to the review, but did not change the direc-
tion or magnitude of the results for those outcomes [26].
Studies that had a publication but no registry record
Between 43 and 86% of publications could not be matched
to a ClinialTrials.gov record (Table 1). Many of these stud-
ies were published before 2000, were not randomized con-
trolled trials, or were not conducted in the USA. Studies
conducted outside of the USA that are not published in
ICMJE journals may not face the same regulatory and fund-
ing requirements to register in ClinicalTrials.gov as those
published in the USA or may have been registered in the
registry of their home country. For example, in the tympa-
nostomy tubes project, 172 studies, 54 of which were ran-
domized controlled trials, were not found in the registry
search. Looking at the randomized controlled trials, 22
were older than ClinicalTrials.gov’s inception date of 2000,
and another 13 were not conducted in the USA [25].
The authors of the review on Strategies to improve
mental health care for children and adolescents reached
out to 15 authors to ask them why they had or had not
registered their studies [27]. Mental health in children
and adolescents entail by nature complex and system-
level interventions, which are not standard in clinical tri-
als registries, though this information could be vital to
the next generation of implementation studies on the
critical components of their interventions. Ten authors
replied, six had not attempted to register their studies
and therefore noted no barriers. Of the four that had
registered their studies, three noted no barriers to regis-
tering, one noted a mismatch between the nature of the
study and the purpose of clinicaltrials.gov, and three
questioned the utility of registering studies of complex
interventions in clinicaltrials.gov.
Discussion
Overall, our analysis across these five projects lead to
the conclusion that performing searches of Clinical-
Trials.gov and including available results in analyses had
a minimal effect on the results of the systematic review
projects; of the five projects, only one found enough
evidence to measure whether new information would
change the results of meta-analyses, and their conclusion
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was that the new data did not change the direction or
magnitude of the results [29]. Recent work by Baudard
and colleagues reviewed existing systematic reviews of
pharmaceutical agents. Their analyses also determined
that additional data yield from registries did not change
in the interpretation of the results [30]. Further, for the
five reviews in this project, the records we found were in
large part not sufficient to establish or rule out bias,
including publication bias, time-lag bias, and selective
reporting bias.
While searching registries did not affect the result of
the reviews, registry records do have the potential to add
value to systematic reviews. These searches revealed
studies, outcomes, and results not included in the sys-
tematic reviews. For example, two teams found studies
with results for which there was no matching publica-
tion, and one team was able to add the new results to
meta-analyses [29]; the other was not, because the
results were not given in a format that could be used
[25]. As noted by others, records may contain results for
outcomes that are not reported in the publications, such
as adverse events [31]. However, at this point, many re-
cords do not contain sufficient information to incorpor-
ate new results. We found many records in
Fig. 1 Timing of studies in the omega-3 review. Each line represents a record, with the dots representing the start and end dates as reported in
the registry. Red lines indicate studies in with a record and a publication; black lines indicate studies with a record only. The red dashed line is
the mean start date for studies with a record and a publication. The black dashed line is the mean start date for studies with a record only. The
blue solid line is the date of the ClinicalTrials.gov search. Lines with arrows indicate records that did not give an estimated completion date. In
two cases, no start date was given, so the team used the date of entry into the registry
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ClinicalTrials.gov that did not have results or publica-
tions, and about 30% of these studies were completed
more than 3 years ago. Because only 13 of the 29 studies
with records only that were completed more than 3 years
ago reported results, we could not determine whether
the unpublished studies would have impacted the con-
clusions of our reviews.
Another value of these searches is the opportunity to
compare prospective records with their respective
publications to assess discrepancies between the data in
the review and the registration information in Clinical-
Trials.gov to see whether those discrepancies suggest
bias [8, 32]. In this project, we found discrepancies diffi-
cult to interpret, in part because of the limited informa-
tion in the ClinicalTrials.gov records and the fact that so
many studies are retrospectively registered.
A third value is to document the gaps in evidence and
detail what additional studies are needed to address
these gaps. Registries can be used to refine research
needs, inform whether identified gaps are being ad-
dressed, and provide a record of ongoing research. This,
in turn can be used in combination with the existing
evidence to help determine future research needs.
These potential benefits come at a cost, in terms of
staff time (i.e., in manually screening, matching, and
analyzing records). In the project on treatment for infer-
tility, the team devoted an estimated 74.5 total hours to
the ClinicalTrials.gov searches, screening, and analyzing
new evidence [28]. Better and more consistent reporting
in the major databases, such as MEDLINE, might im-
prove this and even allow for automation. In a study by
Zarin and colleagues in 2011, of the 2324 ClinicalTrials.
gov result entries, only 14% were linked to a PubMed
citation through the NCT number [33].
Limitations
The primary limitation of this project is that it was per-
formed by four separate teams, using different protocols
for different topic areas. While the protocols were similar
in concept, they differed in some specifics. For example,
one project did not look at adverse event data [29].
A second limitation is that two of the projects were
relatively small, including few studies [27, 28], and the
others included a large number of studies that were rela-
tively old, predating ClinicalTrials.gov in many cases and
the results requirement in most [25, 26, 29]. It is
possible that ClinicalTrials.gov will have greater added
utility for newer interventions and larger projects.
A third limitation is that most projects limited their
registry searches to ClinicalTrials.gov and may have
missed studies registered in other trials. However, the
two projects that also searched the WHO ICTRP’s regis-
try found very few new studies, none of which had re-
sults [25, 26].
Finally, it is important to note that this article is sum-
marized from a case series of five systematic reviews, al-
beit on a range of topics, and thus the results should be
interpreted with caution and may not be generalizable.
Conclusion
Searches of ClinicalTrials.gov records did not influence
the conclusions of five systematic review projects, and
we were unable to draw conclusions about reporting bias
due to lack of information in the records. Improved
prospective registration of trials and consistent reporting
of results in ClinicalTrials.gov would go a long way to
make ClinicalTrials.gov records more useful in finding
unpublished information and identifying potential biases.
In addition, more consistent indexing in databases, such
as MEDLINE, and in ClinicalTrials.gov would allow for
better cross-matching of records and publications, lead-
ing to increased utility of these searches for systematic
review projects.
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